Commentary

Video

The Diagnosis and Prevalence of Secondary AML

Author(s):

Harry Erba, MD, PhD,James K. McCloskey, MD

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.

Related Videos
Ashkan Emadi, MD, PhD
Peter Riedell, MD
Lori A Leslie, MD
Andrew Ip, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Related Content
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
January 6th 2025

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

Andre Henri Goy, MD
December 18th 2024

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

Margaret A. Shipp, MD, of Dana-Farber
December 31st 2024

Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Guillermo Garcia-Manero, MD
December 29th 2024

Paying It Forward: The Importance of Mentorship in a Medical Career

Joseph A. Sparano, MD, FACP
December 23rd 2024

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care